1984 Volume 32 Issue Supplement9 Pages 343-348
Laboratory and clinical studies on AC-1370 were performed and the following results were obtained.
1) Minimum inhibitory concentration (MIC) of AC-1370 were determined in 172 clinical isolates of S. aureus (25 strains) and Gram-negative bacilli (E. coli, K. pneumoniae, S. marcescens, Proteus and P. aeruginosa) compared with those of CPZ. Although the activity of AC-1370 was equal to that of CPZ against P.mirabilis, it was several grades inferior to CPZ against S. aureus and other Gram-negative bacilli.
2) Clinical trial of AC-1370 was performed in 16 patients, 10 with pneumonia, 1 with lung abscess, 2 with acute bronchitis, 1 with acute bronchiolitis, 1 with D.P.B. and 1 with biliary tract infection. Response of respiratory tract infections was excellent in 2, good in 9, fair in 3 and poor in 1, and that of biliary tract infection was fair. Effectiveness rate was 68.8%. Bacteriologically, organisms were eradicated in 3 cases (1 with S. pneumoniae and 2 with E. agglomerans), and replaced in 1 case (P. aeruginosa, Acinetobacter) out of 4 from whom causative organism was detected before therapy.
3) Side effect and adverse reactions were observed in 8 out of 16 cases including skin eruption with eosinophilia (3)(with elevation of GOT and Al-P (1) and with that of GPT (1)), elevation of transaminase (3), decrease of WBC and RBC (1) and positive coombs test (1), respectively.
